The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH 2022 | Improving outcomes for patients with R/R myeloma
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the challenges associated with treating patients with relapsed/refractory (R/R) myeloma. Dr Ramasamy first discusses the psychological burden of relapsed disease, and then mentions the promise of novel combination therapies in improving treatment options for these patients. Following this, Dr Ramasamy explains the need to improve access to BCMA-targeted therapies and the excitement surrounding the future use of chimeric antigen receptor T-cell (CAR-T) therapy in patients who are triple-class refractory. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
